Glytrin (Glyceryl Trinitrate)

Glytrin is indicated for the acute relief and prophylaxis of angina pectoris associated with coronary artery disease, and it may be employed in various clinical situations where rapid onset of action is essential.

• Immediate relief of chest pain during an angina attack.
• Prevention of angina episodes in patients with known stable angina.
• Use in emergency settings where rapid vasodilation is required.
• Adjunct therapy for patients undergoing diagnostic stress testing.
• Management of angina in patients who cannot tolerate other anti‑anginal agents.

The safety profile of Glytrin reflects the pharmacology of nitrate vasodilators, with most patients experiencing mild, transient reactions, while rare but serious events may occur.

Common

• Headache, often described as throbbing, occurring shortly after administration.
• Flushing or warmth sensation in the face and neck.
• Dizziness or light‑headedness, especially when standing quickly.
• Hypotension manifested as a feeling of faintness.
• Nausea or upset stomach, usually mild and transient.
• Palpitations or awareness of heartbeat.

Serious

• Severe hypotension leading to syncope.
• Reflex tachycardia with rapid heart rate.
• Allergic reactions such as rash, itching, or swelling.
• Methemoglobinemia, a rare blood disorder causing cyanosis.
• Worsening chest pain suggesting myocardial ischemia.

When prescribing Glytrin, clinicians consider several precautions to minimize risks and ensure safe use in patients with cardiovascular or other systemic conditions.

• Assess blood pressure before dosing; avoid use in patients with severe hypotension.
• Evaluate for concurrent use of phosphodiesterase‑5 inhibitors, as combined vasodilation can cause profound hypotension.
• Monitor for tolerance development; nitrate-free intervals may be required to maintain efficacy.
• Use with caution in patients with recent myocardial infarction or unstable angina.
• Consider dose adjustment in hepatic impairment due to altered metabolism.
• Advise patients to remain seated or lying down after sublingual administration to reduce risk of dizziness.

Glytrin may interact with other medications that influence vascular tone or nitric‑oxide pathways, requiring careful review of a patient’s drug regimen.

Avoid

• Concomitant use of phosphodiesterase‑5 inhibitors (e.g., sildenafil, tadalafil) due to risk of severe hypotension.
• Co‑administration with other nitrates or nitroglycerin preparations, which can cause additive vasodilatory effects.
• Use with potent vasodilators such as hydralazine or calcium‑channel blockers that may amplify blood pressure lowering.

Use with caution

• Beta‑blockers, as they may mask tachycardia signs of hypotension.
• Diuretics, which can potentiate volume depletion and hypotension.
• Antihypertensive agents, requiring monitoring of blood pressure response.
• ACE inhibitors or ARBs, monitor for additive blood pressure effects.